CDMO Market Overview and 2026 Outlook
The global CDMO (Contract Development and Manufacturing Organization) market is projected to surpass $300 billion in 2026, growing at a CAGR of over 8.5% from approximately $280 billion in 2025. In Korea, major players such as Samsung Biologics, SK Bioscience, and Lotte Biologics continue to expand capacity, driving rapid domestic market growth.
The Paradigm Shift from CMO to CDMO
The transition from simple contract manufacturing (CMO) to full-service CDMO — integrating development capabilities with production — is accelerating, driven by three key factors.
In 2026, CDMO demand for ADCs is expected to increase by more than 35% year-over-year, while the CGT sector faces growing supply constraints as the FDA approval pipeline continues to expand.
CDMO Utilization Strategies for SME Biotech Companies
Build vs. Outsource Decision Framework
The first critical question for small and mid-sized biotech companies is whether to build in-house manufacturing or partner with a CDMO. This decision should be evaluated across four dimensions.
Seven Key Criteria for Selecting a CDMO Partner
Technology Transfer and IP Protection
Technology transfer is the make-or-break phase of any CDMO engagement. When transferring cell lines, process parameters, and analytical methods, companies must establish a Technology Transfer Protocol (TTP) upfront with clearly defined acceptance criteria at each stage. For IP protection, it is essential to define the ownership of Background IP and Foreground IP at the contracting stage.
CDMO Contract Essentials and Risk Management
Core Contract Document Structure
CDMO agreements typically comprise three core documents.
Risk Allocation and GMP Compliance
Batch failures and timeline delays are common occurrences in CDMO projects. Contracts must clearly specify Root Cause Analysis (RCA) procedures and cost-sharing ratios. In particular, parties should pre-agree on who bears raw material costs in the event of drug substance (DS) batch failure, along with remanufacturing timelines and cost allocation.
With joint MFDS-FDA inspections becoming more frequent, it is critical to include a detailed inspection responsibility matrix within the Quality Agreement to ensure clear role delineation between the CDMO and sponsor.
CDMO Market Entry Strategy and Government Support
The Korean government has designated bio CDMO as a national strategic industry and is actively pursuing supportive policies.
KITIM provides end-to-end consulting services covering CDMO strategy development, government funding program alignment, and GMP facility planning. If you need expert guidance on CDMO market entry or partner selection, please reach out through our [Contact](/contact) page.